An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus

Endoscopy

Volumn 41, Issue 5, 2009, Pages 400-408

  Das, A ^a   Wells, C ^a   Kim, H J ^a   Fleischer, D E ^a   Crowell, M D ^a   Sharma, V K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; HUMAN; MALE; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATION; PRECANCER; PROBABILITY; REPRODUCIBILITY; STATISTICAL MODEL; STATISTICS; SURVIVAL;

ADENOCARCINOMA; BARRETT ESOPHAGUS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; POSTOPERATIVE COMPLICATIONS; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 67849108418     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0029-1214612     Document Type: Article

References (75)

1. Spechler S. Clinical practice. Barrett's esophagus. N Engl J Med 2002; 346: 836-842
2. Fitzgerald RC, Saeed IT, Khoo D et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46: 1892-1898 (Pubitemid 32844155)
3. Corley DA, Levin TR, Habel LA et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640 (Pubitemid 34173814)
4. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-1895
5. Boyer J, Laugier R, Chemali Met al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus. Endoscopy 2007; 39: 840-842 (Pubitemid 47386837)
6. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006; 55: 442
7. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-186 (Pubitemid 36231623)
8. Sampliner RE. Endoscopic ablative therapy for Barrett's esophagus: current status. Gastrointest Endosc 2004; 59: 66
9. Johnston MH. Technology insight: ablative techniques for Barrett's esophagus - current and emerging trends. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 323-330
10. Dulai GS, Jensen DM, Cortina G et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005; 61: 232-240 (Pubitemid 40261071)
11. Sharma VK,Wang KK, Overholt BF et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow- up of 100 patients. Gastrointest Endosc 2007; 65: 185-195 (Pubitemid 46157125)
12. Peters FP, Krishnadath KK, Rygiel AM et al. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities. Am J Gastroenterol 2007; 102: 1853-1861 (Pubitemid 47301502)
13. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338 (Pubitemid 24013155)
14. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258 (Pubitemid 26337709)
15. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004; 53: 1736-1744 (Pubitemid 39556888)
16. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2: 868-879 (Pubitemid 39335793)
17. Vij R, Triadafilopoulos G, Owens DK et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2004; 60: 739-756 (Pubitemid 39550931)
18. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96: 316-325 (Pubitemid 38256276)
19. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 2003; 124: 1758-1766 (Pubitemid 36666772)
20. E Arias. United States life tables, 2003. National vital statistic reports; vol 54 no. 4. Hyattsville, MD: National Center for Health Statistics, 2006
21. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-1619 (Pubitemid 32523480)
22. Weston AP, Sharma P, Topalovski M et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 1888-1893
23. Hameeteman W, Tytgat GN, Houthoff HJ et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256 (Pubitemid 19126659)
24. Sharma P, Morales TG, Bhattacharyya A et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92: 2012-2016 (Pubitemid 27476240)
25. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94: 3413-3419
26. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar- lined (Barrett's) esophagus. N Engl JMed 1985; 313: 857-859 (Pubitemid 15250200)
27. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-215 (Pubitemid 27076463)
28. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome ofmedical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-2338 (Pubitemid 32424101)
29. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-2042 (Pubitemid 29374529)
30. Shaheen NJ, Crosby MA, Bozymski EM et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-338 (Pubitemid 30621983)
31. Katz D, Rothstein R, Schned A et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-541 (Pubitemid 29080999)
32. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 927-933 (Pubitemid 14040468)
33. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999; 94: 3420-346
34. Winters Jr C, Spurling TJ, Chobanian SJ et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-124 (Pubitemid 17207669)
35. Streitz JMJ, Andrews CWJ, Ellis FH, Jr. Endoscopic, surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-387
36. Menke-PluymersMB, Schoute NW, Mulder AH et al. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut 1992; 33: 1454-1458
37. Pera M, Trastek VF, Carpenter HA et al. Barrett's esophagus with highgrade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992; 54: 199-204
38. Peters JH, Clark GW, Ireland AP et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-821
39. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: longterm results. Gastrointest Endosc 2003; 58: 183-188 (Pubitemid 38220265)
40. Sharma P,Wani S,Weston AP et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 2006; 55: 1233-1239 (Pubitemid 44277352)
41. Zaninotto G, Parenti AR, Ruol A et al. Oesophageal resection for highgrade dysplasia in Barrett's oesophagus. Br J Surg 2000; 87: 1102-1105 (Pubitemid 30496863)
42. Patti MG, Corvera CU, Glasgow RE et al. A hospital's annual rate of esophagectomy influences the operative mortality rate. J Gastrointest Surg 1998; 2: 186-192 (Pubitemid 128432031)
43. Bousamra M, Haasler GB, and Parviz M. A decade of experience with transthoracic and transhiatal esophagectomy. Am J Surg 2002; 183: 162-167 (Pubitemid 34248031)
44. Lerut T, Coosemans W, Van Raemdonck D et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg 1994; 107: 1059-1065
45. McLarty AJ, Deschamps C, Trastek VF et al. Esophageal resection for cancer of the esophagus: long-term function and quality of life. Ann Thorac Surg 1997; 63: 1568-1572 (Pubitemid 27321515)
46. Chan MF. Complications of upper gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 1996; 6: 287-303 (Pubitemid 26116043)
47. Kavic SM, Basson MD. Complications of endoscopy. Am J Surg 2001;181: 319-332 (Pubitemid 32595678)
48. Arrowsmith JB, Gerstman BB, Fleischer DE et al. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991; 37: 421-427
49. Hart R, Classen M. Complications of diagnostic gastrointestinal endoscopy. Endoscopy 1990; 22: 229-233 (Pubitemid 20334034)
50. Hernandez LJ, Jacobson JW, Harris MS. Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures. Gastrointest Endosc 2000; 51: 460-462 (Pubitemid 30204767)
51. Iannettoni MD, Vlessis AA,Whyte RI et al. Functional outcome after surgical treatment of esophageal perforation. Ann Thorac Surg 1997; 64: 1606-1609
52. Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671-676 (Pubitemid 35216854)
53. Montgomery E, Bronner MP, GoldblumJR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-378 (Pubitemid 32378298)
54. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-2053 (Pubitemid 29374530)
55. Provenzale D, Kemp JA, Arora S et al. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680 (Pubitemid 24132045)
56. Alikhan M, Rex D, Khan A et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999; 50: 23-26 (Pubitemid 29323284)
57. Zaman R, Hapke G, Sahagun G, Katon RM. Unsedated peroral endoscopy with a video ultrathin endoscope: patient acceptance, tolerance, and diagnostic accuracy. Am J Gastroenterol 1998; 93: 1260-1263 (Pubitemid 29076924)
58. de Boer AG, Stalmeier PF, Sprangers MA et al. Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences. Br J Cancer 2002; 86: 851-857 (Pubitemid 34271018)
59. Doubilet P, Begg CB,Weinstein MC et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 157-177 (Pubitemid 16130640)
60. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (Suppl. 2): S68-S80 (Pubitemid 28175944)
61. Heitjan DF. Fieller's method and net health benefit. Health Econ 2000; 9: 327-335 (Pubitemid 30398435)
62. Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S.Multicenter Registry. Gastrointest Endosc 2008; 68: 35-40 (Pubitemid 351902211)
63. Gondrie JJ, Pouw RE, Sondermeijer CM et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. 2008; 40: 370-379
64. Sharma VK, Kim HJ, Das A et al. Circumferential and focal ablation of Barrett esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310-317
65. Gondrie JJ, Pouw RE, Sondermeijer CM et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40: 359-369 (Pubitemid 351696372)
66. Sharma VK, Kim HJ, Das A et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008; 40: 380-387 (Pubitemid 351696374)
67. Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. 2008; 68: 867-876
68. Shaheen NJ, Sharma P, Overholt BF et al. A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial. Gastroenterology 2008; 134: A37
69. Arguedas MR, Eloubeidi MA. Barrett's esophagus: a review of costs of the illness. Pharmacoeconomics 2001; 19: 1003-1011 (Pubitemid 33701930)
70. Weston AP. Automated circumferential Barrett's ablation by using radiofrequency energy: a welcome step in the right direction. Gastrointest Endosc 2007; 65: 196-199 (Pubitemid 46157126)
71. Bergman JJ. Radiofrequency energy ablation of Barrett's esophagus: the best is yet to come! Gastrointest Endosc 2007; 65: 200-202 (Pubitemid 46148922)
72. Inadomi JM, Madanick RD, Somsouk M et al. Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett's esophagus and low-grade dysplasia [abstract]. Gastroenterology 2007; 132: A53
73. Craig BA, Black MA, Sendi PP. Uncertainty in decision models analyzing cost-effectiveness. Med Decis Making 2000; 20: 135-137 (Pubitemid 30036274)
74. Sampliner RE. The better burn. Gastrointest Endosc 2005; 61: 241-242 (Pubitemid 40261072)
75. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc 2001; 76: 438-446 (Pubitemid 32246914)